20-F: Waldencast PLC Files 20-F, Details Indemnification Agreement and Financial Performance

Waldencast PLC files its 20-F, including an indemnification agreement and details on its financial performance for the year ended December 31, 2023.

Summary

• Waldencast PLC has filed its Form 20-F with the SEC, detailing its financial results and an indemnification agreement.
• The document includes audited consolidated financial statements prepared in accordance with U.S. GAAP.
• Waldencast acquired Obagi and Milk Makeup on July 27, 2022, and the report distinguishes between predecessor periods (Obagi only) and successor periods (Waldencast consolidated).
• The company identified material weaknesses in its internal control over financial reporting.
• Waldencast is currently under investigation by the SEC regarding historical accounting practices.
• The company's Class A ordinary shares and warrants are listed on the Nasdaq Capital Market under the symbols WALD and WALDW, respectively.
• An indemnification agreement between Waldencast and its officers and directors is included as an exhibit.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it highlights the company's strategic initiatives and market position, it also acknowledges significant challenges, including an SEC investigation, material weaknesses in internal control, and a substantial net loss. The overall tone is cautious, reflecting the risks and uncertainties associated with the company's current situation.

Positives

• The company is taking steps to remediate the identified material weaknesses in internal control over financial reporting.
• The company is cooperating with the SEC investigation.
• The company has a comprehensive indemnification agreement in place for its directors and officers.

Negatives

• The company is under SEC investigation regarding historical accounting practices.
• Material weaknesses in internal control over financial reporting have been identified.
• The company's financial statements for certain Predecessor Periods have been restated.

Risks

• The SEC investigation could lead to significant costs, penalties, and reputational damage.
• Failure to remediate material weaknesses in internal control could result in inaccurate financial reporting and regulatory sanctions.
• The company's growth strategy may not be successful, and historical growth rates may not be indicative of future performance.
• Failure to comply with covenants under the 2022 Credit Agreement could result in an event of default and acceleration of debt.
• The company is dependent on one main provider in the U.S. who is considered our customer, and the loss of the services of such provider could have a material adverse effect on our business, financial condition and results of operations.
• The company faces intense competition in the skincare and cosmetics industries.
• The company is dependent on third parties to manufacture its products, which exposes it to risks we would not face if we manufactured the products ourselves, including capacity constraints, delay in product deliveries, and the inability to directly control regulatory compliance and quality assurance.
• The loss of a significant customer or inability of a large customer to pay invoices in accordance with agreed-upon payment terms could materially and adversely affect our business, financial condition and results of operations.
• Any damage to our reputation or brands, whether stemming from our use of social media or otherwise, may materially and adversely affect our business, financial condition and results of operations.
• The design, development, manufacture, testing and sale of our products involve the risk of product liability and other claims by consumers and other third parties, and our insurance may be insufficient to cover any such claims.
• Our sales and profitability may suffer if current economic conditions in any of our major markets inhibit people from spending their disposable income on beauty and wellness products.
• Global or regional conflicts or uncertainties may adversely affect our business.
• Our business operations involve doing business in the Peoples Republic of China, which exposes us to risks inherent in doing business in that country.
• Our products containing the active ingredient, hydroquinone, are marketed as prescription-use only drugs but have not received required premarket authorization from the FDA or other regulatory authorities, and the FDA could require us to remove these products from the market until we obtain approval of the required NDA, and we could be found to be marketing and selling these products in violation of the law.
• We may issue additional securities without your approval, which would dilute your ownership interests and may depress the market price of our Class A ordinary shares.
• If we fail to maintain compliance with the continued listing standards of Nasdaq, our securities may be delisted and the price of our Class A ordinary shares and our ability to access the capital markets could be negatively impacted.
• We may be exposed to unknown or contingent liabilities and may be required to subsequently take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and the price of our securities, which could cause you to lose some or all of your investment.
• Warrants will be exercisable for our Class A ordinary shares, which would increase the number of shares eligible for future resale in the public market and result in dilution to our shareholders, and a sale of a substantial number of our securities in the public market could cause the price of our securities to decline.
• A significant number of our shares are held by members of the Sponsor and the former owner of Obagi.

Future Outlook

The company expects capital and operating expenditures to increase over the next several years as it expands its infrastructure, international footprint, distribution channels, and commercialization, clinical trial, research and development, and manufacturing activities.

Industry Context

The report acknowledges the highly competitive market for aesthetic and therapeutic skin health products, with competition from large, well-established companies in the fields of pharmaceuticals, cosmetics, medical devices, and healthcare.

Comparison to Industry Standards

• The report mentions key competitors such as SkinCeuticals, Skinbetter Science, SkinMedica, ZO Skin Health, PCA Skin and EltaMD.
• It notes that many competitors have significantly greater resources, enabling them to make greater investments in R&D and spread their costs over a broader revenue base.
• The report highlights the importance of R&D in the skincare industry and the risk of products becoming obsolete due to competitive advances.

Management Changes

Legal Proceedings

• The company is subject to an ongoing investigation by the SEC regarding historical accounting practices.

Related Party Transactions

• The company has entered into various agreements with Cedarwalk Skincare Ltd., the former owner of Obagi, including an IP License Agreement, a Global Supply Services Agreement, and a Transition Services Agreement.
• The company reimbursed Waldencast Ventures LP, controlled by Michel Brousset, for certain expenses.
• The company has entered into subscription agreements with certain investors, including members of the Sponsor, Michel Brousset, and Hind Sebti.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of additional securities.
• The company's ability to raise capital and the value of its securities could be negatively impacted if it fails to maintain compliance with Nasdaq listing standards.
• The SEC investigation and material weaknesses in internal control could adversely affect the company's reputation and investor perceptions.
• Employees may be affected by changes in compensation and benefits plans.
• Customers may be affected by changes in product offerings and distribution channels.

Next Steps

• The company plans to continue its remediation efforts to address the identified material weaknesses in internal control over financial reporting.
• The company intends to continue expanding its international presence in key locations, such as Asia, Europe, and South America.
• The company plans to continue to innovate Obagis and Milks existing products and anticipate and respond to market trends and changes in consumer preferences.

Key Dates

Keywords

Waldencast, 20-F, financial results, indemnification agreement, SEC investigation, internal control, Obagi, Milk Makeup, risk factors, financial statements